FRS2 and ovarian carcinoma: Previous studies have reported that FRS2, a downstream factor of the FGFR signaling pathway, is repeatedly amplified in high-grade serous ovarian cancer (HGSOC), which accounts for 70–80% of all ovarian carcinomas [55].